Works matching IS 2160763X AND DT 2014 AND VI 3 AND IP 3

Results: 13

Pharmacokinetic bioequivalence crossover study of branded generic and innovator formulations of the cholesterol lowering agent ezetimibe.

Published in:

Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 242, doi. 10.1002/cpdd.80

By:

Palmer, Jonathan L.;
Kunhihitlu, Anil;
Costantini, Andrea;
Esquivel, Florencia;
Roush, John;
Edwards, Karina;
Hill, Thomas W.K.

Publication type:

Article

The effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 202, doi. 10.1002/cpdd.91

By:

Vourvahis, Manoli;
Fang, Juanzhi;
Choo, Heng Wee;
Heera, Jayvant

Publication type:

Article

Issue Information.

Published in:: Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. i, doi. 10.1002/cpdd.66
Publication type:: Article

Evaluation of the effect of ruxolitinib on cardiac repolarization: A thorough QT study.

Published in:

Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 207, doi. 10.1002/cpdd.90

By:

Punwani, Naresh;
Yeleswaram, Swamy;
Chen, Xuejun;
Bowman, Jill;
Soloviev, Maxim;
Williams, William

Publication type:

Article

An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects.

Published in:

Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 229, doi. 10.1002/cpdd.97

By:

Kosoglou, Teddy;
Hubbell, James;
Kantesaria, Bhavna;
Hanson, Mary E.;
Cutler, David L.

Publication type:

Article

Evaluation of the effect of mericitabine at projected therapeutic and supratherapeutic doses on cardiac repolarization in healthy subjects: A thorough QT/QTc study.

Published in:

Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 179, doi. 10.1002/cpdd.79

By:

Chen, Ya‐Chi;
Haznedar, Joshua;
Kulkarni, Rohit;
Vistuer, Christelle;
Washington, Carla;
Liu, Mei;
Smith, Patrick

Publication type:

Article

Sleep-promoting medications: Weighing the hazards of use versus non-use.

Published in:

2014

By:

Greenblatt, David J.

Publication type:

Editorial

Safety, tolerability, pharmacokinetics, and pharmacodynamics of vilanterol, a novel inhaled long-acting β-agonist, in children aged 5-11 years with persistent asthma: A randomized trial.

Published in:

Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 215, doi. 10.1002/cpdd.92

By:

Oliver, Amanda;
VanBuren, Sandi;
Allen, Ann;
Hamilton, Melanie;
Tombs, Lee;
Kempsford, Rodger;
Qaqundah, Paul

Publication type:

Article

Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients.

Published in:

Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 235, doi. 10.1002/cpdd.96

By:

Wang, Huifen Faye;
Qiu, Feng;
Wu, Xiongfe;
Fang, Juanzhi;
Crownover, Penelope;
Korth‐Bradley, Joan;
Schulman, Seth

Publication type:

Article

No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine.

Published in:

Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 187, doi. 10.1002/cpdd.78

By:

Elshoff, Jan‐Peer;
Cawello, Willi;
Andreas, Jens‐Otto;
Braun, Marina

Publication type:

Article

Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device.

Published in:

Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 222, doi. 10.1002/cpdd.94

By:

Kosoglou, Teddy;
Hubbell, James;
Johnson‐Levonas, Amy O.;
Yunan, Mona;
Kantesaria, Bhavna S.;
Cutler, David L.

Publication type:

Article

Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 170, doi. 10.1002/cpdd.98

By:

Xu, Jianfeng;
Gray, Frank;
Henderson, Alex;
Hicks, Kirsty;
Yang, Jiansong;
Thompson, Paul;
Oliver, Johann

Publication type:

Article

The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.

Published in:

Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 194, doi. 10.1002/cpdd.93

By:

Groenendaal, Dorien;
Strabach, Gregory;
Garcia‐Hernandez, Alberto;
Kadokura, Takeshi;
Heeringa, Marten;
Mol, Roelof;
Eltink, Charlotte;
Onkels, Hartmut

Publication type:

Article